Imunon (Nasdaq:IMNN) - Aandelenkoers, Nieuws & Analyse

IMNN Overzicht aandelen

Imunon, Inc., een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën en vaccins voor de behandeling van kanker en infectieziekten.

Over het bedrijf

IMNN fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 19.6% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 meer risico

Imunon, Inc. Concurrenten

Unity Biotechnology

NasdaqGS:UBX

US$22.1m

Kazia Therapeutics

NasdaqCM:KZIA

US$16.4m

AgeX Therapeutics

NYSEAM:AGE

US$31.5m

iBio

NYSEAM:IBIO

US$24.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Imunon
Historische aandelenkoersen
Huidige aandelenkoers	US$0.95
52 Week Hoogtepunt	US$3.65
52 Week Laag	US$0.48
Bèta	2.13
11 maand verandering	-12.04%
3 maanden verandering	-18.10%
1 Jaar Verandering	-12.84%
33 jaar verandering	-92.88%
5 jaar verandering	-94.89%
Verandering sinds IPO	-99.99%

Recent nieuws en updates

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Rendement voor aandeelhouders

	IMNN	US Biotechs	US Markt
7D	-1.7%	-0.7%	-1.6%
1Y	-12.8%	19.8%	30.8%

Rendement versus industrie: IMNN underperformed the US Biotechs industry which returned 20.1% over the past year.

Rendement versus markt: IMNN underperformed the US Market which returned 30.6% over the past year.

Prijsvolatiliteit

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	9.5%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: IMNN has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: IMNN's weekly volatility has decreased from 31% to 9% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1982	33	Stacy Lindborg	imunon.com

Imunon, Inc., een biotechnologiebedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën en vaccins voor de behandeling van kanker en infectieziekten. Het belangrijkste klinische programma van het bedrijf, IMNN-001, is een op DNA gebaseerde immuuntherapie voor de plaatselijke behandeling van eierstokkanker die zich in fase II van de klinische ontwikkeling bevindt. De producten in preklinische fase omvatten IMNN-101, een COVID-19 boostervaccin; IMNN-102 voor de behandeling van het Lassa-virus; en IMNN-201, een Trp2 tumorgeassocieerd antigeen kankervaccin in melanoom.

Imunon, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Imunon zich tot de beurswaarde?
IMNN fundamentele statistieken
Marktkapitalisatie	US$13.68m
Inkomsten(TTM)	-US$18.08m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.8x

Koers/Winstverhouding

Is IMNN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMNN resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$359.30k
Brutowinst	-US$359.30k
Overige uitgaven	US$17.72m
Inkomsten	-US$18.08m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	-1.26
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IMNN op de lange termijn?

Bekijk historische prestaties en vergelijking

IMNN Overzicht aandelen

Beloningen

Risicoanalyse

Imunon, Inc. Concurrenten

NasdaqGS:UBX

US$22.1m

NasdaqCM:KZIA

US$16.4m

NYSEAM:AGE

US$31.5m

NYSEAM:IBIO

US$24.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

Recent updates

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00